Cardiovascular Risk Assessment: A Comparison of the Framingham, PROCAM, and DAD Equations in HIV-Infected Persons

Table 2

Antiretroviral regimen in 195 HIV-infected patients.

Antiretroviral regimen	Class of drug	𝑁 (%)	95% CI
ZDV + 3TC + EFZ	2NRTI + 1NNRTI	122 (62.6)	51.9–74.7
ZDV + 3TC + LPV/RTV	2NRTI + 1PI/Booster	25 (12.8)	8.3–18.9
3TC + TDF + EFZ	2NRTI + 1NNRTI	15 (7.7)	4.3–12.7
3TC + TDF + ATV + RTV	2NRTI + 1PI/Booster	5 (2.6)	0.8–5.9
ZDV + 3TC + TDF + LPV + RTV	3NRTI + 1PI/Booster	3 (1.5)	0.3–4.5
ZDV + 3TC + NVP	2NRTI + 1NNRTI	3 (1.5)	0.3–4.5
Others	—	22 (11.3)	7.0–17.0

ATV: atazanavir; ZDV: zidovudine; 3TC: lamivudine; EFZ: efavirenz; LPV: lopinavir; NNRT: nonnucleoside reverse transcriptase inhibitor; NRTI: nonnucleoside reverse transcriptase inhibitor; NVP: nevirapine; PI: protease inhibitor; RTV: ritonavir; TDF: tenofovir.